Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech Announces Outstanding Q3 Numbers

publication date: Nov 10, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech reported impressive Q3 results, showing that the Shanghai-based CRO is continuing to prosper on all fronts. The company said its revenues were 20% higher than the year-earlier quarter at $83.8 million, and non-GAAP net income rose 27% to $22.4 million. GAAP numbers were even higher as WuXi booked a $30 million breakup fee from Charles River Labs, which decided in Q2 not to proceed with its acquisition of WuXi PharmaTech. More details....

Stock Symbols: (NYSE: WX) (NYSE: CRL)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors